Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
FLUMAZENIL
B. Braun Melsungen AG
0.1 Mg/Ml
Solution for Injection
2007-11-09
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Flumazenil 0.1 mg/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 0.1 mg flumazenil. 1 ampoule with 5 ml contains 0.5 mg flumazenil. 1 ampoule with 10 ml contains 1 mg flumazenil. Excipient: Sodium 3.7 mg / ml. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection concentrate for solution for infusion clear colourless solution pH 3.9 – 5.0 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Flumazenil is indicated for the complete or partial reversal of the central sedative effects of benzodiazepines. It may therefore be used in anaesthesia and in the intensive care in the following situations: In anaesthesia - Termination of hypnosedative effects in general anaesthesia induced and/or maintained with benzodiazepines in hospitalized patients. - Reversal of benzodiazepine sedation in short-term diagnostic and therapeutic procedures in ambulatory patients and hospitalized patients. In intensive care situations - For the specific reversal of the central effects of benzodiazepines, in order to restore spontaneous respiration. - For diagnosis and treatment of intoxications or overdose with only or mainly benzodiazepines. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Flumazenil should be administered intravenously by an anaesthetist or experienced physician. Flumazenil may be administered as injection or as infusion (For instructions on dilution of the product before administration, see section 6.6). Flumazenil may be used concomitantly with other resuscitative measures. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 14/03/2012_ _CRN 2103765_ _page number: 1_ This medicinal pro Read the complete document